I
InnovHeart
Develops transcatheter mitral valve replacement systems to treat patients suffering from mitral valve disease
About InnovHeart
InnovHeart is a medical technology startup that operates in the burgeoning field of mitral valve replacement. The company's primary product is the Saturn Transcatheter Mitral Valve Replacement (TMVR) system, a novel technology that aims to improve the quality of life for millions of people suffering from heart valve diseases. The technology was developed by a team of renowned doctors and researchers, including Dr. Lauren S. Ranard and Dr. Torsten Vahl, in collaboration with the Skirball Center for Innovation and InnovHeart's own R&D team.
The company's business model revolves around the development, licensing, and commercialization of its Saturn TMVR device. InnovHeart recently secured $55 million in Series C financing to further develop this technology. Additionally, the company has entered into an exclusive license agreement with the Grand Pharmaceutical Group to develop and commercialize the Saturn TMVR device in Greater China, indicating a strategic expansion into the Asian market.
InnovHeart is led by David James Wilson, an experienced healthcare and medical device executive, who was recently appointed as the company's CEO. Under his leadership, the company is expected to guide the Saturn TMVR program into its next phase of growth.
InnovHeart's commitment to innovation and learning is evident in its approach to business. The company believes that success lies in continuous innovation and that what worked yesterday may not be sufficient for tomorrow. This philosophy is likely to drive the company's future growth and success in the rapidly evolving MedTech industry.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Milan, Italy
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 68.9/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, medical implants, Cardiology and cardiovascular, Tech for Hospitals and Clinics, Novel Materials, Hard Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jul 2025 | $9.4M | $275M | Fondazione ENEA Tech | ↗ |
| SERIES COther financing | Jan 2022 | $55M | $220M | Genextra · Indaco Venture Partners · China Grand Pharmaceutical and Healthcare Holdings · Panakès Partners | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for InnovHeart is 2.3K monthly website visits, up 1669.2% over the last three months. InnovHeart's team declined 6.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
CDP Venture Capital
Panakès Partners
Indaco Venture Partners
Genextra
Series B and later2 investors entered at this stage
China Grand Pharmaceutical and Healthcare Holdings
Fondazione ENEA Tech
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about InnovHeart on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See InnovHeart’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.